Mast Cell Activation Syndrome
Mast Cell Activation Syndrome: Symptoms, Diagnosis and Support
Mast Cell Activation Syndrome, commonly called MCAS, is associated with recurrent episodes in which mast cells release chemical mediators and produce symptoms across more than one part of the body.1
Symptoms may involve the skin, digestive system, heart and circulation, airways or other systems. Because many of these symptoms also occur in other conditions, diagnosis requires more than a symptom list.
This page explains what MCAS is, the characteristic symptoms, how clinicians assess and treat it, and where re-origin may complement appropriate medical support.
The MCAS resource is educational and non-diagnostic. re-origin does not diagnose or treat MCAS and does not replace care from an allergist, immunologist or other qualified professional.
MCAS at a glance
- What MCAS involves
- Recurrent systemic symptoms caused by mast-cell mediator release.1
- Typical pattern
- Episodes are generally severe, recurrent and involve at least two organ systems.2
- Diagnosis
- Consensus diagnosis combines characteristic symptoms, objective evidence of mediator release and response to mediator-targeted treatment.27
- Testing
- Serum tryptase taken during an episode and compared with a baseline is the most established test. Selected urine mediators may also be useful.64
- Treatment
- Care is individualized and may include trigger management and medicines that block mast-cell mediators or reduce activation.5
- Where re-origin fits
- Complementary support for stress responses, monitoring, avoidance, routines and confidence — not treatment for mast-cell disease.
What symptoms can occur?
Because mast cells sit in tissues throughout the body, an episode tends to look like a cluster of symptoms rather than a single one. What matters clinically is the pattern: symptoms that come in recurrent episodes, involve more than one system and then settle.1
Skin
- Flushing
- Itching
- Hives
- Swelling, or angioedema
Gastrointestinal
- Abdominal cramping
- Diarrhea
- Nausea
- Vomiting
Cardiovascular
- Lightheadedness
- Rapid heart rate
- Low blood pressure
- Fainting or near-fainting
Respiratory
- Wheezing
- Shortness of breath
- Throat tightness
- Nasal symptoms
Systemic or cognitive symptoms
Some people also report headache, fatigue, difficulty concentrating or brain fog. These symptoms are nonspecific: they occur in a very large number of conditions, can occur without any mast-cell involvement, and cannot carry a diagnosis on their own. They are still worth recording and discussing.3
When a reaction may be an emergency
Severe mast-cell activation may present as anaphylaxis. Treat the following as an emergency: difficulty breathing; throat or tongue swelling; collapse or fainting; marked low blood pressure; or a rapidly progressing severe reaction affecting more than one body system.1
Use prescribed epinephrine immediately when directed by the person’s emergency plan and contact local emergency services. Do not wait for a nervous-system practice or other self-management technique to resolve suspected anaphylaxis.
This page does not provide individualized dosing or emergency instructions. Those belong in a written plan agreed with a clinician.
MCAS reflection tool
Organize your symptoms before speaking with a professional
This short reflection tool helps you record which systems are affected, how episodes develop and what to discuss with a clinician. It cannot diagnose MCAS, measure mast-cell mediators or rule out another condition.
Diagnosis requires clinical assessment and, under commonly used consensus criteria, objective evidence of mast-cell mediator release.2
The re-origin approach
How re-origin may support you
Living with unpredictable reactions can begin to affect much more than the reaction itself. People may find themselves closely monitoring food, environments and physical sensations, anticipating the next difficult episode, narrowing routines or losing confidence in ordinary plans.
Medical care remains central for assessing mast-cell activation, managing symptoms, identifying appropriate treatment and preparing for emergencies.
Alongside that care — never in place of it — re-origin provides a structured Program for working with the monitoring, anticipatory stress, avoidance, protective routines and reduced confidence that can build around unpredictable symptoms.
Science-informed neuroplasticity programs, practices, coaching, and community for nervous system regulation. Built by people who’ve lived it. Designed to meet you where you are. Carried by community.
What you can work on with re-origin
- Repeated monitoring of symptoms and possible triggers
- Anticipatory worry before meals, travel or unfamiliar environments
- Stress responses during or after difficult experiences
- Avoidance and increasingly restricted routines
- Reduced confidence following unpredictable reactions
- Applying more flexible responses in everyday life
What is included
What members receive
Science-informed neuroplasticity programs, practices, coaching, and community for nervous system regulation. Built by people who've lived it. Designed to meet you where you are. Carried by community.
Brain retraining
Structured practices that give members opportunities to respond differently to familiar stress, attention and behavioural patterns.
Nervous-system regulation
Develop a wider repertoire of responses for moments when stress, uncertainty or activation feels intense.
Somatic practices
Work with physical activation and body-based responses through gentle practices that can be adapted to the individual.
Neuroplasticity education
Understand how experience, attention, repetition and learning can shape nervous-system responses over time.
Coaching
Get help applying the Program to real-life situations, setbacks and difficult grey areas. Coaching, not psychotherapy.
Community
Connect with people who understand persistent symptoms, nervous-system sensitivity and the effect they can have on everyday life.
Using re-origin in daily life
Support beyond the reaction itself
A medical plan addresses mast-cell mediators, triggers, medication and emergency care. The practical effects of living with unpredictable symptoms can require a different kind of support, sitting alongside that plan rather than in place of it.
This is where the Program’s education, guided practices, coaching and community work together.
Patterns members work with
- Checking and rechecking the body for signs of a reaction
- Anticipatory worry before food, travel or unfamiliar environments
- Routines becoming increasingly narrow after difficult experiences
- Reduced confidence in making plans
- Stress responses that continue after an episode has passed
- Difficulty knowing how to re-engage with everyday life while remaining medically responsible
Related member experience
MCS and Severe Food Sensitivities
Fiona describes her personal experience of living with severe food and chemical sensitivities and using re-origin alongside her wider approach. Her experience relates to some of the practical challenges described on this page, but it is not clinical evidence about MCAS.
This story reflects one person’s experience. Results vary, and a testimonial cannot establish that re-origin treats a health condition or predict another person’s outcome.
The biology
What are mast cells?
Mast cells are immune cells found in tissues throughout the body, particularly near surfaces that meet the outside world — skin, airways and gut lining — and close to blood vessels and nerves. They store and release chemical messengers known as mediators.1
Mast-cell activation is normal and necessary — part of allergic responses, immune defense, inflammation and tissue repair. Having active mast cells is not a malfunction.
MCAS concerns something narrower: inappropriate, excessive or recurrent mediator release producing a characteristic clinical pattern.2
Mediators commonly discussed
- Histamine — itching, flushing and vascular effects
- Tryptase — the enzyme used in the most established test
- Prostaglandins and leukotrienes — lipid mediators, some targeted by medicines
- Cytokines and other signaling substances
Understanding the condition
What is MCAS?
MCAS is not simply a collection of unexplained symptoms. Under commonly used international consensus criteria, it involves recurrent, severe systemic episodes consistent with mast-cell mediator release, objective evidence of increased mediator release during an episode, and improvement with mast-cell-directed treatment.27
Many long-standing, multisystem symptom patterns feel similar from the inside but have very different causes, which is why specialist guidance cautions against diagnosing MCAS from broad or nonspecific symptoms alone.1 The criteria themselves continue to be discussed and refined, and research gaps remain.3
MCAS is not an autoimmune disease, is not established as caused by stress, nervous-system dysregulation, infection or trauma, and is not a label for any multisystem pattern other tests have failed to explain. Other conditions can coexist with it — coexistence is not causation.13
Assessment
How MCAS is diagnosed
Characteristic clinical episodes
Episodes should be recurrent, systemic and consistent with mast-cell mediator release, generally affecting two or more organ systems. Examples of that pattern include:
Long-standing fatigue or brain fog on its own does not meet this criterion.
- Flushing or hives together with gastrointestinal symptoms
- Wheezing together with low blood pressure
- Swelling together with cardiovascular symptoms
Objective evidence of mediator release
An event-related serum tryptase increase of at least 20% above the person's baseline plus 2 ng/mL is the most widely accepted laboratory marker under consensus criteria.67
Other mediator tests Selected urinary mediators — N-methylhistamine, leukotriene E4 and prostaglandin-related metabolites — may add information in some settings, though their availability, validation and interpretation vary between laboratories and countries.4 Chromogranin A, plasma histamine and broad commercial mediator panels are not established as definitive diagnostic tests and can be difficult to interpret without specialist context.3
- Timing matters: the sample is ideally taken soon after a significant event starts
- A later baseline sample is required for comparison
- Results must be interpreted by the treating clinician
- A single normal result does not answer every mast-cell question
Assessment is normally led by an allergist, immunologist or clinician experienced in mast-cell disorders, who can also consider whether another explanation is more likely.
Medical care for MCAS. Support for life around it.
MCAS assessment and treatment belong with qualified clinicians. re-origin focuses on a different part of the experience: the monitoring, stress responses, avoidance, routines and reduced confidence that can build around persistent or unpredictable symptoms.
Members receive a structured Program, guided brain-body practices, somatic tools, optional coaching and a moderated community.
MCAS, mastocytosis, allergy and hereditary alpha-tryptasemia
These terms are often used interchangeably online. They describe different things, and the distinction changes what testing and treatment are appropriate.
MCAS
A syndrome involving systemic mast-cell activation that meets recognized clinical, laboratory and treatment-response criteria.2
Mastocytosis
A separate group of clonal disorders involving abnormal mast-cell accumulation, diagnosed on its own criteria. Systemic mastocytosis is not a symptom of MCAS.2
Allergic reactions
A known allergen may cause secondary mast-cell activation through IgE-mediated or other pathways. That is allergy taking its usual course, not automatically a syndrome.1
Hereditary alpha-tryptasemia
An inherited trait involving extra copies of the alpha-tryptase gene and often a higher baseline serum tryptase. It may modify symptom risk, but it is not automatically MCAS.8
MCAS-like symptoms
Many gastrointestinal, cardiovascular, neurological, allergic and autonomic conditions produce similar symptoms and need appropriate investigation in their own right.3
A note on the "triad"
POTS, Ehlers-Danlos syndrome and MCAS are sometimes described together as an established triad. Co-occurrence has been described, but a universal triad is not settled science and should not be assumed.3
Can MCAS cause neurological or cognitive symptoms?
Some people with mast-cell activation report headache, difficulty concentrating, fatigue, brain fog or dizziness. Those experiences are real and worth raising with a clinician, but they cannot confirm a diagnosis and should not be attributed to neuroinflammation without appropriate evidence.3 No reliable evidence supports the idea that the brain or limbic system creates MCAS through learned threat associations.
Useful things to record for your clinician
- When symptoms started and how they have changed
- Whether they are episodic or continuous
- Which other systems are involved, and how an episode resolves
- Medicines, supplements and recent changes to either
- Anything that reliably precedes an episode
What can trigger mast-cell activation episodes?
Triggers differ considerably between people, and many cannot identify one for every episode.1
Commonly reported
- Allergens
- Insect stings
- Certain medications
- Temperature changes
Also described
- Alcohol
- Physical exertion
- Infection
- Emotional stress and other individual factors
Worth keeping in mind
- A perceived trigger does not reveal the underlying diagnosis
- Extensive indiscriminate avoidance carries nutritional, psychological and practical costs
- Changes to what you avoid are worth discussing with a clinician
- Stress may coincide with or amplify some experiences; that is not proof of psychological causation
Treatment and management
How MCAS is managed
Care is individualized and normally led by an allergist, immunologist or clinician experienced in mast-cell disorders. Controlling the effects of mediator release, preventing severe reactions and treating any underlying allergic, clonal or other condition are legitimate and important objectives in their own right.5
Practical and emergency planning
- Identifying and managing confirmed triggers
- A written emergency plan
- Carrying prescribed epinephrine when clinically indicated
- Management of any underlying allergic, clonal or other condition
Medicines a clinician may consider
- H1 antihistamines
- H2 antihistamines
- Leukotriene-pathway medicines
- Mast-cell stabilizing medicines
- Other specialist treatment for selected patients5
This page does not provide medication schedules or dosages. Which medicines are appropriate, and for how long, is a clinical decision. Supplements and botanicals are not equivalent to prescribed mast-cell stabilizers and can interact with prescribed treatment — tell a clinician or pharmacist about anything you are taking. Do not start, stop or change medication based on this page.
Neuroplasticity and learning
Where the nervous system and neuroplasticity fit
Neuroplasticity describes the nervous system’s ability to change through learning and experience.9 Repeated experience shapes what we attend to, what we anticipate and how readily we return to ordinary activity.
Evidence that stress affects physiology is a different claim from saying that nervous-system practices stop mast-cell degranulation. re-origin does not make the second claim.
What the Program does work with is the rest of it: noticing when monitoring has become constant, loosening routines that narrowed after a difficult episode, settling stress responses that outlast the reaction, and rebuilding confidence in making plans — while the medical plan stays exactly as the clinician set it.
Neuroplasticity may be relevant to attention, habits, anticipation, avoidance and confidence. It does not establish that MCAS was caused by the brain or that nervous-system practices alter mast-cell mediators.
Where the boundary sits
- re-origin does not replace medical treatment or emergency planning
- Practicing calm does not make an unsafe exposure medically safe
- Symptom changes cannot confirm the cause of a reaction
More on MCAS, symptoms and nervous-system health
More on MCAS, symptoms and nervous-system health
MCAS Reflection Tool
Record which systems are affected, how episodes develop and what to raise with a clinician. Educational only — it cannot diagnose MCAS.
Science and Results
See what the re-origin Program is built on, what it is designed to support and what it does not claim to do.
Coaching at re-origin
Understand what coaching involves, what coaches do and — just as importantly — what they do not do.
The re-origin Community
See how the moderated community works and what members use it for day to day.
Related Member Experiences
Individual accounts from members living with sensitivities and unpredictable symptoms. Experiences vary and cannot predict another person's outcome.
Questions
Frequently asked questions
What is Mast Cell Activation Syndrome?
MCAS describes recurrent, severe episodes in which mast cells release chemical mediators and produce symptoms in more than one organ system.1
Consensus criteria combine that pattern with objective evidence of mediator release during an episode and improvement with mast-cell-directed treatment. A list of long-standing symptoms is not sufficient on its own.2
What are the most characteristic symptoms of MCAS?
The most characteristic pattern is episodic and systemic: flushing, itching, hives or swelling together with gastrointestinal, cardiovascular or respiratory symptoms such as cramping, diarrhea, lightheadedness, rapid heart rate, low blood pressure, wheezing or throat tightness.1
How is MCAS diagnosed?
What is the tryptase 20% plus 2 rule?
It is the most widely accepted laboratory marker of mast-cell activation under consensus criteria. A serum tryptase measured during or soon after an episode is compared with the person’s own baseline, and an increase of at least 20% above baseline plus 2 ng/mL supports mast-cell activation.7
Can someone have MCAS with a normal baseline tryptase?
A normal baseline does not by itself rule out an episodic increase, because the comparison that matters is between an event sample and the person’s own baseline.6
Equally, a raised baseline tryptase does not confirm MCAS. It may reflect hereditary alpha-tryptasemia, a clonal mast-cell disorder or other causes.8
Is MCAS the same as mastocytosis?
No. Mastocytosis is a separate group of clonal disorders involving abnormal accumulation of mast cells, and it is diagnosed on its own criteria. Systemic mastocytosis is not a symptom of MCAS.2
How is MCAS treated?
Care is individualized. It may include managing confirmed triggers, a written emergency plan, carrying prescribed epinephrine where clinically indicated, H1 and H2 antihistamines, leukotriene-pathway medicines, mast-cell stabilizing medicines, other specialist treatment in selected cases, and management of any underlying allergic or clonal condition.5
Can stress worsen symptoms?
Some people describe stress among the factors that coincide with or appear to amplify their symptoms. That is not the same as stress causing MCAS, and it does not mean the condition is psychological.
Does re-origin treat MCAS?
No. re-origin is complementary education, brain-body practices, somatic tools, coaching and community. It does not diagnose MCAS, block mast-cell mediators, prevent anaphylaxis or replace medical treatment.
When should someone seek emergency help?
Seek emergency help immediately for difficulty breathing, throat or tongue swelling, collapse or fainting, marked low blood pressure, or a rapidly progressing severe reaction affecting more than one body system.
Use prescribed epinephrine immediately when directed by the person’s emergency plan and contact local emergency services.
Support for life around unpredictable symptoms
Unpredictable reactions can affect routines, confidence, food choices, travel and the way someone responds to everyday sensations and environments. Medical assessment, treatment and emergency planning remain central.
Alongside that care, re-origin provides science-informed education, brain-body practices, somatic tools, coaching and community for people who want structured support working with monitoring, stress responses, avoidance and reduced confidence.
Medical disclaimer
The information on this page is provided for educational purposes only. It is not intended to diagnose, treat, cure or prevent any condition and does not replace assessment, diagnosis or treatment from qualified healthcare professionals. Do not start, stop or change medication or treatment based on this page. Seek appropriate medical advice for new, severe, worsening or unexplained symptoms.
References
- Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. Journal of Allergy and Clinical Immunology. 2019;144(4):883–896. doi:10.1016/j.jaci.2019.08.023. View the DOI record View source
- Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646. doi:10.1097/HS9.0000000000000646. View the DOI record View source
- Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: current understanding and research needs. Journal of Allergy and Clinical Immunology. 2024;154(2):255–263. doi:10.1016/j.jaci.2024.05.025. View the DOI record View source
- Pongdee T, et al. Urine mast cell mediators in the evaluation and diagnosis of mast cell activation syndrome. Current Allergy and Asthma Reports. 2024. doi:10.1007/s11882-024-01128-y. View the DOI record View source
- Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo DG. Mast cell-targeting therapies in mast cell activation syndromes. Current Allergy and Asthma Reports. 2024;24(2):63–71. doi:10.1007/s11882-023-01123-9. View the DOI record View source
- Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(4):1125–1133.e1. doi:10.1016/j.jaip.2019.01.006. View the DOI record View source
- Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. Journal of Allergy and Clinical Immunology. 2010;126(6):1099–1104.e4. doi:10.1016/j.jaci.2010.08.035. View the DOI record View source
- Robey RC, Wilcock A, Bonin H, et al. The clinical features of hereditary alpha-tryptasemia — implications for interdisciplinary practice. Deutsches Ärzteblatt International. 2024;121(8):258–264. doi:10.3238/arztebl.m2023.0287. View the DOI record View source
- Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011;134(6):1591–1609. doi:10.1093/brain/awr039. View the DOI record View source